|
PT1523496E
(pt)
|
2002-07-18 |
2011-09-29 |
Merus B V |
Produção de misturas de anticorpos de forma recombinante
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2006106905A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
会合制御によるポリペプチド製造方法
|
|
US11046784B2
(en)
|
2006-03-31 |
2021-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
EP4218801A3
(en)
|
2006-03-31 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
CA2664738C
(en)
|
2006-09-29 |
2017-03-07 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
CA2686827C
(en)
|
2006-12-14 |
2014-09-16 |
Aileron Therapeutics, Inc. |
Bis-sulfhydryl macrocyclization systems
|
|
WO2008104000A2
(en)
|
2007-02-23 |
2008-08-28 |
Aileron Therapeutics, Inc. |
Triazole macrocycle systems
|
|
ES2610531T3
(es)
|
2007-03-28 |
2017-04-28 |
President And Fellows Of Harvard College |
Polipéptidos cosidos
|
|
CN104497143B
(zh)
|
2007-03-29 |
2020-08-25 |
健玛保 |
双特异性抗体及其制造方法
|
|
ES2687808T3
(es)
|
2007-09-26 |
2018-10-29 |
Chugai Seiyaku Kabushiki Kaisha |
Región constante de anticuerpo modificado
|
|
SI2202245T1
(sl)
|
2007-09-26 |
2016-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
EP2235064B1
(en)
*
|
2008-01-07 |
2015-11-25 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
KR20110014607A
(ko)
|
2008-04-29 |
2011-02-11 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
UY31861A
(es)
|
2008-06-03 |
2010-01-05 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
MX2010013239A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
CA2729100C
(en)
|
2008-06-26 |
2018-01-02 |
Acceleron Pharma Inc. |
Methods for dosing an activin-actriia antagonist and monitoring of treated patients
|
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
|
WO2010019702A2
(en)
|
2008-08-12 |
2010-02-18 |
Oncomed Pharmaceuticals, Inc. |
Ddr1-binding agents and methods of use thereof
|
|
CA2744088A1
(en)
|
2009-01-14 |
2010-07-22 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
WO2010084197A1
(en)
*
|
2009-01-26 |
2010-07-29 |
Genmab A/S |
Methods for producing mixtures of antibodies
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
|
PE20120770A1
(es)
|
2009-03-25 |
2012-07-10 |
Genentech Inc |
ANTICUERPOS ANTI alfa5ß1 CON ACTIVIDAD SOBRE GLIOBLASTOMAS
|
|
EP2417156B1
(en)
|
2009-04-07 |
2015-02-11 |
Roche Glycart AG |
Trivalent, bispecific antibodies
|
|
AU2013203859B2
(en)
*
|
2009-04-27 |
2016-09-08 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
ES2708124T3
(es)
|
2009-04-27 |
2019-04-08 |
Oncomed Pharm Inc |
Procedimiento para preparar moléculas heteromultiméricas
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
MX342623B
(es)
|
2009-06-26 |
2016-10-06 |
Regeneron Pharma |
Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
|
|
AU2010270844A1
(en)
|
2009-07-08 |
2011-12-22 |
Amgen Inc. |
Design of stable and aggregation free antibody Fc molecules through CH3 domain interface engineering
|
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
US9493578B2
(en)
*
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
|
US20130072439A1
(en)
|
2009-09-22 |
2013-03-21 |
Huw M. Nash |
Peptidomimetic macrocycles
|
|
EP2481752B1
(en)
|
2009-09-24 |
2016-11-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
RU2012119756A
(ru)
|
2009-10-15 |
2013-11-20 |
Эбботт Лэборетриз |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
|
WO2011047383A1
(en)
|
2009-10-16 |
2011-04-21 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
AU2010321720B2
(en)
*
|
2009-11-23 |
2017-03-02 |
Amgen Inc. |
Monomeric antibody Fc
|
|
JP5856073B2
(ja)
*
|
2009-12-29 |
2016-02-09 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
Ｒｏｎ結合構築体およびその使用方法
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
NZ719253A
(en)
|
2010-02-08 |
2022-08-26 |
Regeneron Pharma |
Common light chain mouse
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
KR101899835B1
(ko)
|
2010-03-24 |
2018-09-19 |
제넨테크, 인크. |
항-ｌｒｐ６ 항체
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
CA3079122A1
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US20130101590A1
(en)
|
2010-04-09 |
2013-04-25 |
Heather A. Arnett |
Btnl9 proteins, nucleic acids, and antibodies and uses thereof
|
|
CN103097417B
(zh)
|
2010-04-20 |
2019-04-09 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
|
AU2016219622A1
(en)
*
|
2010-04-20 |
2016-09-15 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
JP2019048814A
(ja)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
EP2560683B2
(en)
|
2010-04-23 |
2022-07-20 |
F. Hoffmann-La Roche AG |
Production of heteromultimeric proteins
|
|
JP6022444B2
(ja)
*
|
2010-05-14 |
2016-11-09 |
ライナット ニューロサイエンス コーポレイション |
ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CN103154035B
(zh)
|
2010-05-27 |
2017-05-10 |
根马布股份公司 |
针对her2的单克隆抗体
|
|
CA2794731C
(en)
|
2010-06-18 |
2019-03-19 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
WO2012006503A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
|
CN103109189A
(zh)
|
2010-07-19 |
2013-05-15 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
CN103270418A
(zh)
|
2010-07-19 |
2013-08-28 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
|
|
LT2603530T
(lt)
|
2010-08-13 |
2018-01-25 |
Roche Glycart Ag |
Anti-fap antikūnai ir jų naudojimo metodai
|
|
RU2584597C2
(ru)
|
2010-08-13 |
2016-05-20 |
Рош Гликарт Аг |
Антитела против а2 тенасцина с и способы их применения
|
|
ES2711526T3
(es)
|
2010-08-13 |
2019-05-06 |
Aileron Therapeutics Inc |
Macrociclos peptidomiméticos
|
|
AR082518A1
(es)
|
2010-08-25 |
2012-12-12 |
Hoffmann La Roche |
Anticuerpos contra il-18r1 y usos de los mismos
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
AU2011325833C1
(en)
*
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
ES2607086T3
(es)
|
2010-11-10 |
2017-03-29 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para la inmunoterapia de enfermedades neuronales
|
|
KR101398363B1
(ko)
|
2010-11-17 |
2014-05-22 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
|
CA2818173C
(en)
|
2010-11-30 |
2022-05-03 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
PL2647707T3
(pl)
|
2010-11-30 |
2019-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Środek terapeutyczny wywołujący cytotoksyczność
|
|
CN112168962A
(zh)
|
2010-12-16 |
2021-01-05 |
弗·哈夫曼-拉罗切有限公司 |
与th2抑制相关的诊断和治疗
|
|
KR20140014116A
(ko)
|
2010-12-20 |
2014-02-05 |
제넨테크, 인크. |
항-메소텔린 항체 및 면역접합체
|
|
AU2011348232A1
(en)
|
2010-12-22 |
2013-07-18 |
Genentech, Inc. |
Anti-PCSK9 antibodies and methods of use
|
|
MX355255B
(es)
|
2011-02-04 |
2018-04-11 |
Genentech Inc |
Variantes de fc y métodos para su producción.
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EP2681239B8
(en)
|
2011-02-28 |
2015-09-09 |
F. Hoffmann-La Roche AG |
Antigen binding proteins
|
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
AU2012229048B2
(en)
|
2011-03-16 |
2016-01-21 |
Amgen Inc |
Fc variants
|
|
BR112013023918A2
(pt)
*
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
|
RU2607014C2
(ru)
|
2011-03-29 |
2017-01-10 |
Рош Гликарт Аг |
Fc варианты антитела
|
|
KR20140021589A
(ko)
|
2011-04-07 |
2014-02-20 |
제넨테크, 인크. |
항-fgfr4 항체 및 사용 방법
|
|
AU2012240102C1
(en)
|
2011-04-08 |
2016-09-08 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
|
DK2697257T3
(en)
|
2011-04-13 |
2017-01-30 |
Bristol Myers Squibb Co |
FC FUSION PROTEINS INCLUDING UNKNOWN LINKERS OR EVENTS
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
JP6177231B2
(ja)
*
|
2011-04-20 |
2017-08-09 |
ゲンマブ エー／エス |
Ｈｅｒ２に対する二重特異性抗体
|
|
BR112013026306A2
(pt)
|
2011-04-20 |
2017-09-05 |
Roche Glycart Ag |
MÉTODO E CONSTRUTOS PARA A PASSAGEM DE PENDENTE DO pH DA BARREIRA SANGUE-CÉREBRO
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2012155019A1
(en)
|
2011-05-12 |
2012-11-15 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
EA030462B1
(ru)
|
2011-05-16 |
2018-08-31 |
Дженентек, Инк. |
Агонисты fgfr1 и способы их применения
|
|
CA2837914A1
(en)
|
2011-06-15 |
2012-12-20 |
F. Hoffmann-La Roche Ag |
Anti-human epo receptor antibodies and methods of use
|
|
BR112013032630B1
(pt)
*
|
2011-06-30 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídeo heterodimerizado compreendendo região fc de igg
|
|
TW201306866A
(zh)
|
2011-06-30 |
2013-02-16 |
Genentech Inc |
抗－ｃ－ｍｅｔ抗體調配物
|
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
|
EP2543680A1
(en)
*
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
EP2734239A2
(en)
|
2011-07-18 |
2014-05-28 |
Arts Biologics A/S |
Long acting luteinizing hormone (lh) compound
|
|
WO2013014208A2
(en)
*
|
2011-07-27 |
2013-01-31 |
Glaxo Group Limited |
Antigen binding constructs
|
|
SG2014007686A
(en)
|
2011-08-05 |
2014-03-28 |
Regeneron Pharma |
Humanized universal light chain mice
|
|
CN103890007A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
神经调节蛋白抗体及其用途
|
|
RU2605390C2
(ru)
|
2011-08-23 |
2016-12-20 |
Рош Гликарт Аг |
Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
|
|
BR112014003598B1
(pt)
|
2011-08-23 |
2022-05-31 |
Roche Glycart Ag |
Molécula de ligação de antígeno biespecífica, composição farmacêutica e uso da molécula de ligação de antígeno biespecífica
|
|
PE20141521A1
(es)
|
2011-08-23 |
2014-10-25 |
Roche Glycart Ag |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
RU2014109038A
(ru)
|
2011-08-23 |
2015-09-27 |
Рош Гликарт Аг |
Антитела к хондроитинсульфат протеогликану меланомы
|
|
AU2012300279A1
(en)
|
2011-08-26 |
2014-04-03 |
Merrimack Pharmaceuticals, Inc. |
Tandem Fc bispecific antibodies
|
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US20130078252A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
MY173865A
(en)
|
2011-09-22 |
2020-02-25 |
Amgen Inc |
Cd27l antigen binding proteins
|
|
ES2707580T3
(es)
|
2011-09-23 |
2019-04-04 |
Oncomed Pharm Inc |
Agentes de unión a VEGF/DLL4 y usos de los mismos
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CA2850818A1
(en)
|
2011-10-11 |
2013-04-18 |
Genentech, Inc. |
Improved assembly of bispecific antibodies
|
|
CN108373506A
(zh)
|
2011-10-14 |
2018-08-07 |
霍夫曼-拉罗奇有限公司 |
抗HtrA1抗体及使用方法
|
|
EP2766000A2
(en)
|
2011-10-15 |
2014-08-20 |
F.Hoffmann-La Roche Ag |
Scd1 antagonists for treating cancer
|
|
RU2639523C2
(ru)
|
2011-10-18 |
2017-12-21 |
Эйлерон Терапьютикс, Инк. |
Пептидомиметические макроциклы и их применение
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
HUE044633T2
(hu)
|
2011-10-27 |
2019-11-28 |
Genmab As |
Heterodimer fehérjék elõállítása
|
|
AU2012328980A1
(en)
|
2011-10-28 |
2014-04-24 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
RU2681885C2
(ru)
*
|
2011-10-31 |
2019-03-13 |
Чугаи Сейяку Кабусики Кайся |
Антигенсвязывающая молекула с регулируемой конъюгацией между тяжелой цепью и легкой цепью
|
|
CA2854233C
(en)
*
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
|
JP2015505300A
(ja)
|
2011-11-23 |
2015-02-19 |
アムジエン・インコーポレーテツド |
インターフェロンγに対する抗体を使用した治療方法
|
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
|
BR112014015078A2
(pt)
|
2011-12-21 |
2017-06-13 |
Amgen Inc |
polipeptídeos-fc variantes com ligação melhorada ao receptor fc neonatal
|
|
MX2014007262A
(es)
|
2011-12-22 |
2014-08-01 |
Hoffmann La Roche |
Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso.
|
|
SG10201805622QA
(en)
|
2011-12-22 |
2018-08-30 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
|
MX355624B
(es)
|
2011-12-22 |
2018-04-25 |
Hoffmann La Roche |
Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
|
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
|
MX2014008101A
(es)
|
2011-12-30 |
2014-09-25 |
Abbvie Inc |
Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
|
|
CN102558355B
(zh)
*
|
2011-12-31 |
2015-02-25 |
苏州康宁杰瑞生物科技有限公司 |
基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
|
|
SG11201404198TA
(en)
|
2012-01-18 |
2014-08-28 |
Genentech Inc |
Anti-lrp5 antibodies and methods of use
|
|
KR20140119114A
(ko)
|
2012-01-18 |
2014-10-08 |
제넨테크, 인크. |
Fgf19 조절제의 사용 방법
|
|
CN104204218A
(zh)
*
|
2012-01-26 |
2014-12-10 |
安姆根有限公司 |
生长分化因子15 (gdf-15)多肽
|
|
RU2693264C2
(ru)
|
2012-02-03 |
2019-07-01 |
Ф.Хоффман-Ля Рош Аг |
Молекулы биспецифических антител и т-клетки, трансфецированные антигеном, и их применение в медицине
|
|
US20130209473A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
|
MX362492B
(es)
|
2012-02-15 |
2019-01-21 |
Aileron Therapeutics Inc |
Macrociclos peptidomiméticos.
|
|
CA2860600C
(en)
|
2012-02-15 |
2022-07-26 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
|
JP6450192B2
(ja)
|
2012-02-15 |
2019-01-09 |
エイルロン セラピューティクス，インコーポレイテッド |
トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
|
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ３阻害剤に関する診断及び治療
|
|
CA2862516C
(en)
|
2012-03-27 |
2023-02-14 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
BR112014024903A2
(pt)
|
2012-04-05 |
2017-07-11 |
Hoffmann La Roche |
anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
|
|
SI2838918T1
(sl)
|
2012-04-20 |
2019-11-29 |
Merus Nv |
Postopki in sredstva za proizvodnjo heterodimernih IG-podobnih molekul
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
EP2844300B1
(en)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
|
EP2847224A4
(en)
*
|
2012-05-10 |
2016-04-27 |
Zymeworks Inc |
SINGLE ARM MONOVALENT ANTIBODY CONSTRUCTS AND USES THEREOF
|
|
EP2847230B1
(en)
*
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
|
KR102293061B1
(ko)
|
2012-05-21 |
2021-08-23 |
제넨테크, 인크. |
혈액-뇌 장벽 수송의 안전성을 개선하는 방법
|
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
|
EP4310191A3
(en)
|
2012-06-14 |
2024-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified fc region
|
|
US9266961B2
(en)
|
2012-06-15 |
2016-02-23 |
Genentech, Inc. |
Anti-PCSK9 antibodies, formulations, dosing, and methods of use
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
BR112014030843A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo
|
|
EP2870180B1
(en)
|
2012-07-04 |
2024-08-28 |
F. Hoffmann-La Roche AG |
Anti-biotin antibodies and methods of use
|
|
SI2869848T1
(sl)
|
2012-07-04 |
2017-01-31 |
F. Hoffmann-La Roche Ag |
Kovalentno vezani konjugati antigen-protitelo
|
|
CN110042114B
(zh)
|
2012-07-05 |
2024-09-10 |
弗·哈夫曼-拉罗切有限公司 |
表达和分泌系统
|
|
EP2869845B1
(en)
|
2012-07-06 |
2019-08-28 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
EP3632462A1
(en)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
TR201802376T4
(tr)
|
2012-07-09 |
2018-03-21 |
Genentech Inc |
Anti-CD79b antikorları içeren immünokonjugatlar.
|
|
BR112015000437A2
(pt)
|
2012-07-09 |
2017-06-27 |
Genentech Inc |
imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
|
|
WO2014011520A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
|
EP3730512A1
(en)
|
2012-07-13 |
2020-10-28 |
The Trustees of the University of Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
|
CA2878843A1
(en)
*
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Bispecific asymmetric heterodimers comprising anti-cd3 constructs
|
|
AR092027A1
(es)
|
2012-07-13 |
2015-03-18 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
|
|
CN104768571B
(zh)
|
2012-07-13 |
2018-11-09 |
酵活有限公司 |
多价异多聚体支架设计和构建体
|
|
EP2875046B1
(en)
|
2012-07-19 |
2020-02-26 |
Amgen Inc. |
Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
|
CN102851338A
(zh)
*
|
2012-07-25 |
2013-01-02 |
苏州康宁杰瑞生物科技有限公司 |
利用电荷排斥作用制备同二聚体蛋白混合物的方法
|
|
ES2848732T3
(es)
|
2012-08-07 |
2021-08-11 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
CN104704001B
(zh)
|
2012-08-09 |
2019-02-12 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
|
US10919953B2
(en)
|
2012-08-24 |
2021-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
FcgammaRIIB-specific Fc region variant
|
|
JP6774164B2
(ja)
|
2012-08-24 |
2020-10-21 |
中外製薬株式会社 |
マウスＦｃγＲＩＩ特異的Ｆｃ抗体
|
|
CN109793893B
(zh)
|
2012-09-07 |
2023-05-26 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
|
IN2015MN00139A
(es)
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
|
SG10201705787VA
(en)
|
2012-09-27 |
2017-08-30 |
Merus Nv |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
|
WO2014055784A1
(en)
|
2012-10-03 |
2014-04-10 |
Zymeworks Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
EP2905290B1
(en)
|
2012-10-05 |
2019-12-04 |
Kyowa Kirin Co., Ltd. |
Heterodimeric protein composition
|
|
RU2015117393A
(ru)
|
2012-10-08 |
2016-12-10 |
Роше Гликарт Аг |
Лишенные fc антитела, содержащие два Fab-фрагмента, и способы их применения
|
|
EP2914961A4
(en)
|
2012-10-31 |
2016-04-20 |
Oncomed Pharm Inc |
METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4
|
|
TW201811825A
(zh)
|
2012-11-01 |
2018-04-01 |
美商艾伯維有限公司 |
抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
|
|
AU2013337388B2
(en)
|
2012-11-01 |
2018-08-02 |
Aileron Therapeutics, Inc. |
Disubstituted amino acids and methods of preparation and use thereof
|
|
CN110669136A
(zh)
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
EP2917243B1
(en)
|
2012-11-08 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
SG11201503734UA
(en)
|
2012-11-13 |
2015-06-29 |
Genentech Inc |
Anti-hemagglutinin antibodies and methods of use
|
|
JP6571527B2
(ja)
*
|
2012-11-21 |
2019-09-04 |
ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． |
二重特異性抗体
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
EP2927321B1
(en)
|
2012-11-27 |
2021-02-17 |
Ajou University Industry-Academic Cooperation Foundation |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
KR102264570B1
(ko)
|
2012-11-28 |
2021-06-14 |
자임워크스 인코포레이티드 |
가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
EP2940135B9
(en)
|
2012-12-27 |
2021-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
|
WO2014108198A1
(en)
|
2013-01-10 |
2014-07-17 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP3620473A1
(en)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Novel heterodimeric proteins
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10487155B2
(en)
*
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
|
KR101993714B1
(ko)
|
2013-01-30 |
2019-06-28 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
대사 장애를 치료하는데 이용하기 위한 조성물과 방법
|
|
CA2900764A1
(en)
*
|
2013-02-08 |
2014-08-14 |
Stemcentrx, Inc. |
Novel multispecific constructs
|
|
ES2645634T3
(es)
|
2013-02-12 |
2017-12-07 |
Bristol-Myers Squibb Company |
Métodos de replegado de proteínas a elevado pH
|
|
WO2014126871A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
LT2956471T
(lt)
*
|
2013-02-15 |
2024-06-10 |
R-Pharm International, Llc |
Il-1beta inhibitoriaus kompozicija ir jos naudojimas
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
WO2014131711A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
NZ708182A
(en)
|
2013-02-26 |
2019-08-30 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
JP2016512489A
(ja)
|
2013-02-26 |
2016-04-28 |
ロシュ グリクアート アーゲー |
抗ｍｃｓｐ抗体
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
KR20150123250A
(ko)
|
2013-03-06 |
2015-11-03 |
제넨테크, 인크. |
암 약물 내성의 치료 및 예방 방법
|
|
JP2016510755A
(ja)
|
2013-03-06 |
2016-04-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗Ｃ−ＭＥＴタンデムＦｃ二重特異性抗体
|
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
EP3486255A3
(en)
*
|
2013-03-13 |
2019-11-13 |
Ibentrus Inc. |
Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
US20140271634A1
(en)
|
2013-03-14 |
2014-09-18 |
The Regents Of The University Of California |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
WO2014153030A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
BR112015022019A2
(pt)
|
2013-03-14 |
2017-08-29 |
Genentech Inc |
Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
|
|
JP6466904B2
(ja)
|
2013-03-15 |
2019-02-06 |
ヤンセン バイオテツク，インコーポレーテツド |
インターフェロンアルファ及びオメガ抗体アンタゴニスト
|
|
TW201512219A
(zh)
|
2013-03-15 |
2015-04-01 |
Abbvie Inc |
針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
|
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
|
AU2014236769B2
(en)
*
|
2013-03-15 |
2018-09-27 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
SG11201507427QA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
JP6594855B2
(ja)
*
|
2013-03-15 |
2019-10-23 |
ゼンコア インコーポレイテッド |
ヘテロ二量体タンパク質
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2902910A1
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
SG10201701380TA
(en)
|
2013-03-15 |
2017-04-27 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
CN105339001A
(zh)
|
2013-03-15 |
2016-02-17 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
BR112015021521A2
(pt)
|
2013-03-15 |
2017-10-10 |
Genentech Inc |
anticorpos anti-crth2 e métodos para seu uso
|
|
MX2015013288A
(es)
|
2013-03-18 |
2016-04-07 |
Biocerox Prod Bv |
Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos.
|
|
CN113621057A
(zh)
|
2013-04-02 |
2021-11-09 |
中外制药株式会社 |
Fc区变体
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
UA118029C2
(uk)
|
2013-04-29 |
2018-11-12 |
Ф. Хоффманн-Ля Рош Аг |
Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
|
|
EP2992010B1
(en)
*
|
2013-04-29 |
2021-03-24 |
F.Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
EP2992011B1
(en)
|
2013-04-29 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
PL3594240T3
(pl)
|
2013-05-20 |
2024-04-02 |
F. Hoffmann-La Roche Ag |
Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
|
|
ES2973474T3
(es)
|
2013-05-30 |
2024-06-20 |
Kiniksa Pharmaceuticals Ltd |
Proteínas de enlace a antígeno del receptor de oncostatina M
|
|
KR102363220B1
(ko)
|
2013-07-05 |
2022-02-15 |
젠맵 에이/에스 |
인간화 또는 키메라 cd3 항체
|
|
BR112016002213A2
(pt)
|
2013-07-31 |
2017-08-29 |
Amgen Inc |
Construtos do fator 15 de diferenciação de crescimento (gdf-15)
|
|
DK3041862T3
(da)
*
|
2013-09-05 |
2020-07-27 |
Igm Biosciences Inc |
Modificerede bispecifikke, penta- og hexavalente ig-m-antistoffer med konstant kæde
|
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
|
US20160257748A1
(en)
|
2013-09-25 |
2016-09-08 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
EP3050896B1
(en)
*
|
2013-09-27 |
2021-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
EP3055329B1
(en)
|
2013-10-11 |
2018-06-13 |
F. Hoffmann-La Roche AG |
Multispecific domain exchanged common variable light chain antibodies
|
|
CA2926084A1
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Nsp4 inhibitors and methods of use
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
KR20160068802A
(ko)
|
2013-10-23 |
2016-06-15 |
제넨테크, 인크. |
호산구성 장애를 진단 및 치료하는 방법
|
|
PE20160856A1
(es)
|
2013-11-06 |
2016-09-03 |
Janssen Biotech Inc |
Anticuerpos anti-ccl17
|
|
CA2930307A1
(en)
|
2013-11-13 |
2015-05-21 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
|
LT3071597T
(lt)
|
2013-11-21 |
2020-10-12 |
F. Hoffmann-La Roche Ag |
Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
|
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
|
CN110590950A
(zh)
|
2013-12-13 |
2019-12-20 |
基因泰克公司 |
抗cd33抗体和免疫缀合物
|
|
JP6608827B2
(ja)
|
2013-12-20 |
2019-11-20 |
エフ．ホフマン−ラ ロシュ アーゲー |
ヒト化抗タウ（ｐＳ４２２）抗体及び使用方法
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
EP4043493A1
(en)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
|
CN105873615B
(zh)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
共价连接的helicar-抗helicar抗体缀合物及其用途
|
|
RU2682754C2
(ru)
|
2014-01-03 |
2019-03-21 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью
|
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
|
EP3093295B1
(en)
|
2014-01-08 |
2020-05-27 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
Il-15 heterogeneous dimer protein and uses thereof
|
|
EP3094648A1
(en)
|
2014-01-15 |
2016-11-23 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
|
WO2015107026A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
JP2017505305A
(ja)
|
2014-01-24 |
2017-02-16 |
ジェネンテック， インコーポレイテッド |
抗ｓｔｅａｐ１抗体及びイムノコンジュゲートを使用する方法
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
CA2938731A1
(en)
|
2014-02-08 |
2015-08-13 |
Genentech, Inc. |
Methods of treating alzheimer's disease
|
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
|
MX2016010433A
(es)
|
2014-02-12 |
2016-09-22 |
Genentech Inc |
Anticuerpos anti-jagged1 y metodos de uso.
|
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
MX2016011155A
(es)
|
2014-02-28 |
2017-02-22 |
Merus Nv |
Anticuerpo que une erbb-2 y erbb-3.
|
|
CA2941030A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus N.V. |
Antibodies that bind egfr and erbb3
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3116999B1
(en)
|
2014-03-14 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Methods and compositions for secretion of heterologous polypeptides
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
WO2015143414A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
WO2015148531A1
(en)
|
2014-03-24 |
2015-10-01 |
Genentech, Inc. |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
CN111410691B
(zh)
|
2014-03-28 |
2024-02-13 |
Xencor公司 |
结合至cd38和cd3的双特异性抗体
|
|
PL3126394T3
(pl)
|
2014-03-31 |
2020-05-18 |
F.Hoffmann-La Roche Ag |
Przeciwciała anty-OX40 i sposoby stosowania
|
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
|
US20170022291A1
(en)
|
2014-04-01 |
2017-01-26 |
Adimab, Llc |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
JP6666262B2
(ja)
|
2014-04-02 |
2020-03-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体の軽鎖誤対合を検出するための方法
|
|
UA117289C2
(uk)
*
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
ES2900898T3
(es)
|
2014-04-07 |
2022-03-18 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecíficos inmunoactivadores
|
|
US20190202908A1
(en)
*
|
2014-04-15 |
2019-07-04 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
SG11201607070VA
(en)
*
|
2014-05-02 |
2016-11-29 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
CN106471117A
(zh)
|
2014-05-06 |
2017-03-01 |
豪夫迈·罗氏有限公司 |
使用哺乳动物细胞产生异多聚体蛋白
|
|
KR102246800B1
(ko)
|
2014-05-13 |
2021-04-30 |
바이오아트라, 인코퍼레이티드 |
조건부 활성 생체 단백질
|
|
CA2947157A1
(en)
|
2014-05-13 |
2015-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
ES2936810T3
(es)
*
|
2014-05-16 |
2023-03-22 |
Pfizer |
Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
|
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック， インコーポレイテッド |
抗ｇｐｃ３抗体及びイムノコンジュゲート
|
|
WO2015179835A2
(en)
|
2014-05-23 |
2015-11-26 |
Genentech, Inc. |
Mit biomarkers and methods using the same
|
|
EP3107938B1
(en)
|
2014-05-28 |
2022-05-04 |
Zymeworks Inc. |
Modified antigen binding polypeptide constructs and uses thereof
|
|
US10010498B2
(en)
|
2014-06-04 |
2018-07-03 |
Acceleron Pharma Inc. |
Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
|
|
MA51075A
(fr)
|
2014-06-04 |
2020-10-14 |
Acceleron Pharma Inc |
Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
|
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
|
US11123426B2
(en)
|
2014-06-11 |
2021-09-21 |
The Trustees Of Dartmouth College |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
|
WO2015191986A1
(en)
|
2014-06-13 |
2015-12-17 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
JP6654581B2
(ja)
|
2014-06-26 |
2020-02-26 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗ｂｒｄｕ抗体および使用方法
|
|
AU2015279321B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma, S.A. |
Multispecific antigen binding proteins
|
|
AU2015279316B2
(en)
|
2014-06-27 |
2021-03-04 |
Innate Pharma |
Multispecific NKp46 binding proteins
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
PL3164492T3
(pl)
|
2014-07-03 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Układy ekspresji polipeptydu
|
|
CN107074925B
(zh)
|
2014-07-10 |
2021-08-24 |
阿费里斯股份公司 |
用于预防和/或治疗亨廷顿氏病的物质和方法
|
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
ME03665B
(me)
|
2014-07-11 |
2020-10-20 |
Genmab As |
Antitela koja vezuju axl
|
|
KR20170029490A
(ko)
|
2014-07-11 |
2017-03-15 |
제넨테크, 인크. |
노치 경로 억제
|
|
US9777073B2
(en)
*
|
2014-07-21 |
2017-10-03 |
Wuhan Yzy Biopharma Co., Ltd. |
Construction and application of bispecific antibody EpCAM×CD3
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
EP3174897B1
(en)
*
|
2014-07-29 |
2020-02-12 |
F.Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
AP2016009663A0
(en)
|
2014-07-30 |
2016-12-31 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
MX2017001556A
(es)
*
|
2014-08-04 |
2017-05-15 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t.
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
ES2913865T3
(es)
|
2014-08-28 |
2022-06-06 |
Bioatla Inc |
Receptores de antígeno quimérico condicionalmente activos para células T modificadas
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
EP3189152A4
(en)
|
2014-09-03 |
2018-04-04 |
BioAtla LLC |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
SG11201701867SA
(en)
|
2014-09-09 |
2017-04-27 |
Janssen Biotech Inc |
Combination therapies with anti-cd38 antibodies
|
|
CN114106185A
(zh)
|
2014-09-12 |
2022-03-01 |
基因泰克公司 |
抗her2抗体和免疫缀合物
|
|
MX2017003022A
(es)
|
2014-09-12 |
2017-05-12 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados.
|
|
EP3191518B1
(en)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
TW201625688A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
經半胱胺酸改造之抗體及接合物
|
|
MX2017003247A
(es)
|
2014-09-15 |
2017-11-30 |
Amgen Inc |
Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
PL3194443T3
(pl)
|
2014-09-17 |
2022-01-31 |
Novartis Ag |
Nakierowywanie komórek cytotoksycznych za pośrednictwem receptorów chimerycznych do immunoterapii adoptywnej
|
|
WO2016049214A1
(en)
|
2014-09-23 |
2016-03-31 |
Genentech, Inc. |
METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
|
|
SG11201702175YA
(en)
|
2014-09-24 |
2017-04-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and formulations thereof
|
|
KR20170058424A
(ko)
|
2014-09-24 |
2017-05-26 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티드모방 거대고리 및 이의 용도
|
|
WO2016046778A2
(en)
|
2014-09-25 |
2016-03-31 |
Amgen Inc |
Protease-activatable bispecific proteins
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
CA2963692A1
(en)
|
2014-10-09 |
2016-04-14 |
Engmab Ag |
Bispecific antibodies against cd3epsilon and ror1
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016061389A2
(en)
|
2014-10-16 |
2016-04-21 |
Genentech, Inc. |
Anti-alpha-synuclein antibodies and methods of use
|
|
TN2017000113A1
(en)
|
2014-10-31 |
2018-07-04 |
Ngm Biopharmaceuticals Inc |
Compositions and methods of use for treating metabolic disorders
|
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
DK3215528T3
(da)
|
2014-11-06 |
2019-10-07 |
Hoffmann La Roche |
Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
EP3842453A1
(en)
|
2014-11-06 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
EP3217787B1
(en)
|
2014-11-10 |
2019-04-17 |
F.Hoffmann-La Roche Ag |
Animal model for nephropathy and agents for treating the same
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
RS60201B1
(sr)
|
2014-11-14 |
2020-06-30 |
Hoffmann La Roche |
Antigen vezujući molekuli koji sadrže trimer liganda familije tnf
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
LT3789402T
(lt)
|
2014-11-20 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
WO2016086196A2
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
LT3223845T
(lt)
|
2014-11-26 |
2021-08-25 |
Xencor, Inc. |
Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
|
MA40938A
(fr)
|
2014-12-05 |
2017-10-11 |
Hoffmann La Roche |
Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
|
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
|
MX2017007491A
(es)
|
2014-12-10 |
2018-05-04 |
Genentech Inc |
Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
|
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
|
KR20170094787A
(ko)
|
2014-12-18 |
2017-08-21 |
에프. 호프만-라 로슈 아게 |
Cdc 유발 항체를 측정하기 위한 검정 및 방법
|
|
EP3233907B1
(en)
*
|
2014-12-19 |
2021-03-03 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
|
KR102650420B1
(ko)
|
2014-12-19 |
2024-03-21 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
CN110658340B
(zh)
*
|
2015-01-08 |
2023-10-31 |
苏州康宁杰瑞生物科技有限公司 |
具有共同轻链的双特异性抗体或抗体混合物
|
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
MA41375A
(fr)
|
2015-01-22 |
2017-11-28 |
Lilly Co Eli |
Anticorps igg bispécifiques et leurs procédés de préparation
|
|
AU2015380397B2
(en)
|
2015-01-31 |
2021-10-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
US9969800B2
(en)
|
2015-02-05 |
2018-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
IL-8 antibodies
|
|
US10859726B2
(en)
|
2015-03-03 |
2020-12-08 |
Schlumberger Technology Corporation |
Multi-mode acoustic tool and method
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
AR103852A1
(es)
|
2015-03-06 |
2017-06-07 |
Genentech Inc |
DsbA Y DsbC ULTRAPURIFICADOS Y SUS MÉTODOS DE PREPARACIÓN Y USO
|
|
CN107430117A
(zh)
|
2015-03-16 |
2017-12-01 |
豪夫迈·罗氏有限公司 |
检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
|
|
CN107438622A
(zh)
|
2015-03-19 |
2017-12-05 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
EP3294318A4
(en)
|
2015-03-20 |
2019-04-03 |
Aileron Therapeutics, Inc. |
PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
|
|
CN107636154A
(zh)
*
|
2015-03-26 |
2018-01-26 |
阿塞勒隆制药公司 |
促滤泡素抑制素相关的融合蛋白及其用途
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
SG10201913158PA
(en)
|
2015-04-03 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
|
JP7055636B2
(ja)
|
2015-04-06 |
2022-04-18 |
アクセルロン ファーマ インコーポレイテッド |
ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
|
|
CN113683708A
(zh)
|
2015-04-06 |
2021-11-23 |
阿塞勒隆制药公司 |
单臂i型和ii型受体融合蛋白和其用途
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
IL254887B2
(en)
|
2015-04-07 |
2023-11-01 |
Alector Llc |
Anti-sortilin antibodies and methods of using them
|
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
US10851144B2
(en)
|
2015-04-10 |
2020-12-01 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
WO2016164708A1
(en)
|
2015-04-10 |
2016-10-13 |
Adimab, Llc |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
KR20170138494A
(ko)
|
2015-04-17 |
2017-12-15 |
엘살리스 비오떼끄 |
항-ｔｙｒ０３ 항체 및 이의 용도
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
|
JP6952605B2
(ja)
|
2015-04-24 |
2021-10-20 |
ジェネンテック， インコーポレイテッド |
多特異性抗原結合タンパク質
|
|
WO2016183104A1
(en)
|
2015-05-11 |
2016-11-17 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
IL295002A
(en)
|
2015-05-12 |
2022-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
|
BR112017024877A2
(pt)
|
2015-05-20 |
2019-09-17 |
Janssen Biotech, Inc. |
anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
|
|
EP3303400B1
(en)
|
2015-05-28 |
2020-09-09 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
|
PL3303632T5
(pl)
|
2015-05-29 |
2023-07-03 |
F. Hoffmann-La Roche Ag |
Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
|
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
TWI790642B
(zh)
|
2015-06-05 |
2023-01-21 |
美商建南德克公司 |
抗-tau抗體及使用方法
|
|
CN107750164A
(zh)
|
2015-06-08 |
2018-03-02 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
|
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
CN108064246A
(zh)
|
2015-06-15 |
2018-05-22 |
基因泰克公司 |
抗体和免疫结合物
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
AU2016280102B2
(en)
|
2015-06-16 |
2022-06-16 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
CA2986592A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
|
WO2016209921A1
(en)
|
2015-06-22 |
2016-12-29 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
EP3313881A1
(en)
|
2015-06-23 |
2018-05-02 |
Innate Pharma |
Multispecific nk engager proteins
|
|
PL3313441T3
(pl)
|
2015-06-24 |
2024-08-19 |
Janssen Biotech, Inc. |
Immunomodulacja i leczenie guzów litych przeciwciałami swoiście wiążącymi cd38
|
|
MX2017016647A
(es)
|
2015-06-24 |
2019-04-25 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
|
EP3744732A1
(en)
|
2015-06-24 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
US11536716B2
(en)
|
2015-06-25 |
2022-12-27 |
Hoffmann-La Roche Inc. |
Cell based assay for determining antibody or ligand binding and function
|
|
CA2989936A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
EP3313878B1
(en)
|
2015-06-29 |
2021-09-15 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
|
US10059741B2
(en)
|
2015-07-01 |
2018-08-28 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
|
US20180201693A1
(en)
|
2015-07-09 |
2018-07-19 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
PL3319993T3
(pl)
|
2015-07-10 |
2020-07-27 |
Genmab A/S |
Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
|
|
SI3115376T1
(sl)
|
2015-07-10 |
2018-12-31 |
Merus N.V. |
Humana protitelesa, ki vežejo CD3
|
|
UA128057C2
(uk)
|
2015-07-15 |
2024-03-27 |
Ґенмаб А/С |
Гуманізоване або химерне антитіло, яке зв'язує cd3 людини
|
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
MX2018001227A
(es)
|
2015-07-30 |
2018-03-26 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas.
|
|
MX2018001522A
(es)
|
2015-08-05 |
2018-03-15 |
Janssen Biotech Inc |
Anticuerpos anti-cd154 y metodos de uso de estos.
|
|
SI3331902T1
(sl)
|
2015-08-07 |
2021-09-30 |
ALX Oncology Inc. |
Konstrukti z domeno SIRP-alfa ali njegove različice
|
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
ES2964640T3
(es)
|
2015-08-13 |
2024-04-08 |
Amgen Inc |
Filtración en profundidad cargada de proteínas de unión al antígeno
|
|
AU2016312259B2
(en)
|
2015-08-26 |
2018-12-06 |
Bison Therapeutics Inc. |
Multispecific antibody platform and related methods
|
|
CN108348551A
(zh)
|
2015-08-28 |
2018-07-31 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
|
CN108135932A
(zh)
|
2015-08-28 |
2018-06-08 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
|
US10221249B2
(en)
|
2015-09-10 |
2019-03-05 |
Affigen, Llc |
Method of making patient specific anti-idiotype antibodies
|
|
JP2018528217A
(ja)
|
2015-09-10 |
2018-09-27 |
エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
|
|
WO2017049004A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
|
TWI814162B
(zh)
|
2015-09-18 |
2023-09-01 |
日商中外製藥股份有限公司 |
Il-8結合抗體及其用途
|
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
|
MY191756A
(en)
|
2015-09-23 |
2022-07-14 |
Genentech Inc |
Optimized variants of anti-vegf antibodies
|
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
|
MX2018003533A
(es)
|
2015-09-24 |
2019-04-25 |
Abvitro Llc |
Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso.
|
|
CN113956358A
(zh)
|
2015-09-25 |
2022-01-21 |
豪夫迈·罗氏有限公司 |
抗tigit抗体和使用方法
|
|
EP4435105A2
(en)
|
2015-09-29 |
2024-09-25 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
WO2017055389A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
|
|
AU2016329126B2
(en)
|
2015-10-02 |
2023-04-13 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for PD1 and TIM3
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
SI3356404T1
(sl)
|
2015-10-02 |
2021-11-30 |
F. Hoffmann-La Roche Ag |
Protitelesa proti PD1 in postopki uporabe
|
|
JP7239320B2
(ja)
*
|
2015-10-02 |
2023-03-14 |
エフ． ホフマン－ラ ロシュ アーゲー |
多重特異性抗体
|
|
JP2018533930A
(ja)
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
CN108602887B
(zh)
|
2015-10-02 |
2022-06-21 |
豪夫迈·罗氏有限公司 |
对共刺激性tnf受体特异性的双特异性抗体
|
|
JP6937746B2
(ja)
|
2015-10-02 |
2021-09-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ｃｄ１９×ｃｄ３ｔ細胞活性化抗原結合分子
|
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体に対する四価の二重特異性抗体発明の分野
|
|
WO2017059551A1
(en)
|
2015-10-08 |
2017-04-13 |
Zymeworks Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
CN108602888B
(zh)
|
2015-10-23 |
2022-10-04 |
美勒斯公司 |
抑制癌症生长的结合分子
|
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
WO2017075212A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
|
MA43187B1
(fr)
|
2015-11-03 |
2021-02-26 |
Janssen Biotech Inc |
Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
|
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック， インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
UA125611C2
(uk)
|
2015-12-14 |
2022-05-04 |
Макродженікс, Інк. |
Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
|
|
CN106883297B
(zh)
*
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
|
CR20180365A
(es)
|
2015-12-16 |
2018-09-28 |
Amgen Inc |
PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
|
|
WO2017106810A2
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
WO2017106684A2
(en)
|
2015-12-17 |
2017-06-22 |
Janssen Biotech, Inc. |
Antibodies specifically binding hla-dr and their uses
|
|
PE20240365A1
(es)
|
2015-12-18 |
2024-03-04 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
|
MX2018007781A
(es)
|
2015-12-28 |
2018-09-05 |
Chugai Pharmaceutical Co Ltd |
Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
|
|
WO2017117179A1
(en)
*
|
2015-12-28 |
2017-07-06 |
Massachusetts Institute Of Technology |
Bispecific antibodies having constant region mutations and uses therefor
|
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
|
CN108602883A
(zh)
|
2016-01-20 |
2018-09-28 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック， インコーポレイテッド |
がんのための治療方法及び診断方法
|
|
JP2019513347A
(ja)
|
2016-03-04 |
2019-05-30 |
ノバルティス アーゲー |
複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
|
|
KR20180116215A
(ko)
|
2016-03-14 |
2018-10-24 |
추가이 세이야쿠 가부시키가이샤 |
암의 치료에 이용하기 위한 세포상해 유도 치료제
|
|
AU2017238172B2
(en)
|
2016-03-21 |
2024-06-27 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
HUE061946T2
(hu)
|
2016-03-22 |
2023-09-28 |
Hoffmann La Roche |
Proteáz-aktivált T-sejt bispecifikus molekulák
|
|
PT3433280T
(pt)
|
2016-03-22 |
2023-06-15 |
Hoffmann La Roche |
Moléculas biespecíficas das células t ativadas pela protease
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
|
SG11201807279QA
(en)
|
2016-03-31 |
2018-09-27 |
Ngm Biopharmaceuticals Inc |
Binding proteins and methods of use thereof
|
|
WO2017177013A1
(en)
|
2016-04-06 |
2017-10-12 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
KR102459684B1
(ko)
|
2016-04-15 |
2022-10-26 |
바이오아트라, 인코퍼레이티드 |
항 Axl항체 및 이의 면역접합체와 이것들의 용도
|
|
DK3443096T5
(da)
|
2016-04-15 |
2024-09-09 |
Novartis Ag |
Sammensætninger og fremgangsmåder til selektiv ekspression af kimære antigenreceptorer
|
|
CA3020848A1
(en)
|
2016-04-15 |
2017-10-19 |
Janssen Pharmaceuticals, Inc. |
Anti-human vista antibodies and use thereof
|
|
KR102474757B1
(ko)
|
2016-04-20 |
2022-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
|
|
IL262266B1
(en)
|
2016-04-20 |
2024-09-01 |
Regeneron Pharma |
Compositions and methods for preparing antibodies based on the use of LOCI amplifying expression
|
|
EP3889175A1
(en)
|
2016-05-02 |
2021-10-06 |
F. Hoffmann-La Roche AG |
The contorsbody - a single chain target binder
|
|
JP7422480B2
(ja)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
|
HRP20221298T1
(hr)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
WO2017201036A1
(en)
|
2016-05-17 |
2017-11-23 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
CN109152843A
(zh)
|
2016-05-20 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
CA3025306A1
(en)
|
2016-05-23 |
2017-11-30 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
|
JP7301540B2
(ja)
|
2016-05-26 |
2023-07-03 |
チールー ピュージェット サウンド バイオセラピューティクス コーポレイション |
抗体の混合物
|
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
|
US10787518B2
(en)
|
2016-06-14 |
2020-09-29 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
EP3472177B1
(en)
|
2016-06-17 |
2024-08-14 |
F. Hoffmann-La Roche AG |
Purification of multispecific antibodies
|
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
CN109790526A
(zh)
|
2016-07-01 |
2019-05-21 |
分解治疗有限责任公司 |
优化的二核酸酶融合体和方法
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
KR102632202B1
(ko)
|
2016-07-14 |
2024-02-02 |
젠맵 에이/에스 |
Cd40 및 cd137에 대한 다중특이적 항체
|
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
DK3496739T3
(da)
|
2016-07-15 |
2021-05-10 |
Acceleron Pharma Inc |
Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
|
|
JP2019530641A
(ja)
*
|
2016-07-19 |
2019-10-24 |
アイベントラス・インコーポレイテッドＩｂｅｎｔｒｕｓ，Ｉｎｃ． |
二重特異性タンパク質およびその製造方法
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
EP3487867A2
(en)
|
2016-07-22 |
2019-05-29 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
|
CA3031909A1
(en)
|
2016-07-27 |
2018-02-01 |
Acceleron Pharma Inc. |
Methods and compositions for treating myelofibrosis
|
|
BR112019001570A2
(pt)
|
2016-07-28 |
2019-07-09 |
Novartis Ag |
terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
|
|
CN117986372A
(zh)
|
2016-07-29 |
2024-05-07 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
|
WO2018026942A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Merrimack Pharmaceuticals, Inc. |
Heteromeric polypeptides
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
CN110267977A
(zh)
|
2016-08-10 |
2019-09-20 |
亚洲大学校产学协力团 |
细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物
|
|
CN109689111B
(zh)
|
2016-08-11 |
2024-04-05 |
基因泰克公司 |
吡咯并苯并二氮杂䓬前药及其抗体缀合物
|
|
WO2018038046A1
(ja)
|
2016-08-22 |
2018-03-01 |
中外製薬株式会社 |
ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
|
RU2752785C2
(ru)
|
2016-09-23 |
2021-08-04 |
Дженентек, Инк. |
Применение антагонистов il-13 для лечения атопического дерматита
|
|
EP3504234A4
(en)
|
2016-09-29 |
2020-12-02 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
HETERODIMER IMMUNOGLOBULIN CONSTRUCTS AND MANUFACTURING PROCESSES
|
|
WO2018060301A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against cd3
|
|
JP6785372B2
(ja)
|
2016-09-30 |
2020-11-18 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
|
|
JP2019529509A
(ja)
|
2016-10-05 |
2019-10-17 |
アクセレロン ファーマ インコーポレーテッド |
腎臓疾患を治療するための組成物および方法
|
|
CN110036025B
(zh)
|
2016-10-05 |
2024-03-22 |
阿塞勒隆制药公司 |
变体ActRIIB蛋白及其用途
|
|
BR112019006993A2
(pt)
|
2016-10-05 |
2019-09-03 |
Acceleron Pharma Inc |
heteromultímeros de alk4:actriib e usos dos mesmos
|
|
EP3522933B1
(en)
|
2016-10-05 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Methods for preparing antibody drug conjugates
|
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
AU2017342560B2
(en)
|
2016-10-14 |
2022-03-17 |
Xencor, Inc. |
IL15/IL15Ralpha heterodimeric Fc-fusion proteins
|
|
WO2018075692A2
(en)
|
2016-10-19 |
2018-04-26 |
Invenra Inc. |
Antibody constructs
|
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
|
EP3535291A1
(en)
|
2016-11-01 |
2019-09-11 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
JP2019534044A
(ja)
|
2016-11-08 |
2019-11-28 |
クイル ピュージェット サウンド バイオセラピューティクス コーポレーション |
抗ｐｄ１および抗ｃｔｌａ４抗体
|
|
EP3538555A1
(en)
|
2016-11-14 |
2019-09-18 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
BR112019010051A2
(pt)
|
2016-11-18 |
2019-09-03 |
Beijing Hanmi Pharmaceutical Co Ltd |
anticorpo biespecífico heterodimérico, polinucleotídeo isolado, vetor de expressão recombinante, célula hospedeira, composição, método de produzir o anticorpo biespecífico heterodimérico, uso do anticorpo bieífico heterodimérico, e método de prevenir e/ou tratar uma doença
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
US20230192896A1
(en)
|
2016-11-23 |
2023-06-22 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
TW202328181A
(zh)
|
2016-12-07 |
2023-07-16 |
美商建南德克公司 |
抗-tau抗體及使用方法
|
|
JP7141407B2
(ja)
|
2016-12-13 |
2022-09-22 |
エフ．ホフマン－ラ ロシュ アーゲー |
腫瘍試料における標的抗原の存在を決定する方法
|
|
TWI829628B
(zh)
|
2016-12-19 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
與靶向4-1bb (cd137)促效劑併用之組合療法
|
|
AU2017384126A1
(en)
|
2016-12-20 |
2019-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
|
|
JP7215999B2
(ja)
|
2016-12-21 |
2023-01-31 |
エフ．ホフマン－ラ ロシュ アーゲー |
抗体またはリガンドの結合および機能を決定するためのアッセイ法
|
|
JP6931058B2
(ja)
|
2016-12-21 |
2021-09-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗体のインビトロ糖鎖工学における酵素の再使用
|
|
MX2019006266A
(es)
|
2016-12-21 |
2019-08-21 |
Hoffmann La Roche |
Glucomanipulacion in vitro de anticuerpos.
|
|
EP3559249A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
WO2018115262A1
(en)
|
2016-12-23 |
2018-06-28 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
CR20190309A
(es)
|
2017-01-03 |
2019-08-21 |
Hoffmann La Roche |
Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
|
|
BR112019013955A2
(pt)
|
2017-01-06 |
2020-02-11 |
Momenta Pharmaceuticals, Inc. |
Composições e métodos relacionados a construtos de fc manipulados
|
|
EP3568468A4
(en)
|
2017-01-12 |
2020-12-30 |
Eureka Therapeutics, Inc. |
RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
WO2018144784A1
(en)
|
2017-02-01 |
2018-08-09 |
Smet Pharmaceutical Inc. |
MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
|
|
RU2019128134A
(ru)
|
2017-02-07 |
2021-03-09 |
Дайити Санкио Компани, Лимитед |
Антитело против gprc5d и молекула, содержащая антитело
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
US10738131B2
(en)
|
2017-02-10 |
2020-08-11 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
AU2018219348A1
(en)
*
|
2017-02-10 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Proteins binding BCMA, NKG2D and CD16
|
|
CA3053222A1
(en)
|
2017-02-10 |
2018-08-16 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
CA3235295A1
(en)
|
2017-02-20 |
2018-08-23 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
EP3586872A4
(en)
|
2017-02-24 |
2020-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
PHARMACEUTICAL COMPOSITION, ANTIG-BINDING MOLECULES, TREATMENT METHODS AND SCREENING METHODS
|
|
WO2018160841A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
CN118063619A
(zh)
|
2017-03-02 |
2024-05-24 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
|
CN116836285A
(zh)
|
2017-03-09 |
2023-10-03 |
健玛保 |
针对pd-l1的抗体
|
|
CA3052357A1
(en)
|
2017-03-10 |
2018-09-13 |
F. Hoffmann-La Roche Ag |
Method for producing multispecific antibodies
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
CN110891611B
(zh)
|
2017-03-22 |
2024-03-29 |
阿森迪斯制药公司 |
水凝胶交联透明质酸前药组合物和方法
|
|
MA48996A
(fr)
|
2017-03-28 |
2020-02-05 |
Genentech Inc |
Méthodes de traitement de maladies neurodégénératives
|
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
|
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
|
|
US20200270359A1
(en)
|
2017-03-31 |
2020-08-27 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
MX2019011660A
(es)
|
2017-03-31 |
2019-11-18 |
Merus Nv |
Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
|
|
SG11201909156RA
(en)
|
2017-04-01 |
2019-10-30 |
Beijing hanmi pharm co ltd |
Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof
|
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
SG11201909218RA
(en)
|
2017-04-03 |
2019-11-28 |
Hoffmann La Roche |
Antibodies binding to steap-1
|
|
ES2928718T3
(es)
|
2017-04-03 |
2022-11-22 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15
|
|
CN110402255B
(zh)
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
|
KR102408873B1
(ko)
|
2017-04-05 |
2022-06-15 |
에프. 호프만-라 로슈 아게 |
Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체
|
|
DK3606954T3
(en)
|
2017-04-05 |
2022-09-26 |
Hoffmann La Roche |
Anti-LAG3-antistoffer
|
|
MX2019012198A
(es)
|
2017-04-11 |
2020-01-21 |
Inhibrx Inc |
Constructos de polipéptidos multiespecíficos que tienen unión limitada a cd3 y métodos de utilización de los mismos.
|
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
SG11201909728XA
(en)
|
2017-04-26 |
2019-11-28 |
Eureka Therapeutics Inc |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
US20210246227A1
(en)
|
2017-05-31 |
2021-08-12 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
US20200247897A1
(en)
|
2017-06-07 |
2020-08-06 |
Genmab B.V. |
Therapeutic antibodies based on mutated igg hexamers
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
JP7433910B2
(ja)
|
2017-06-22 |
2024-02-20 |
ノバルティス アーゲー |
Ｃｄ７３に対する抗体分子及びその使用
|
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
|
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
MY202336A
(en)
|
2017-07-11 |
2024-04-24 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
EP3655023A1
(en)
|
2017-07-20 |
2020-05-27 |
Novartis AG |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
|
JP2020527351A
(ja)
|
2017-07-21 |
2020-09-10 |
ジェネンテック， インコーポレイテッド |
がんの治療法及び診断法
|
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
|
CA3071211A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
MA49846A
(fr)
|
2017-08-09 |
2020-06-17 |
Merus Nv |
Anticorps qui se lient à l'egfr et à cmet
|
|
CN111295394B
(zh)
|
2017-08-11 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
抗cd8抗体及其用途
|
|
KR20200039778A
(ko)
|
2017-08-22 |
2020-04-16 |
사나바이오, 엘엘씨 |
가용성 인터페론 수용체 및 그의 용도
|
|
SG11201810270SA
(en)
|
2017-09-29 |
2019-04-29 |
Chugai Pharmaceutical Co Ltd |
Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
|
|
AU2018347521A1
(en)
|
2017-10-12 |
2020-05-07 |
Immunowake Inc. |
VEGFR-antibody light chain fusion protein
|
|
CN111246885B
(zh)
*
|
2017-10-20 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
从单特异性抗体生成多特异性抗体的方法
|
|
MX2020004100A
(es)
|
2017-10-30 |
2020-07-24 |
Hoffmann La Roche |
Metodo para generacion in vivo de anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
WO2019086499A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
|
BR112020008031A2
(pt)
|
2017-11-01 |
2020-10-27 |
F. Hoffmann-La Roche Ag |
anticorpo multiespecíficos, método para a preparação do anticorpo multiespecífico, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira e composição farmacêutica
|
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
|
BR112020007630A2
(pt)
|
2017-11-01 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo biespecífico ox40, produto farmacêutico, composição farmacêutica e anticorpos biespecíficos anti-fap/ anti-ox40
|
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
US11484573B2
(en)
|
2017-11-09 |
2022-11-01 |
Keros Therapeutics, Inc. |
Activin receptor type IIa variants and methods of use thereof
|
|
WO2019099838A1
(en)
|
2017-11-16 |
2019-05-23 |
Novartis Ag |
Combination therapies
|
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
EP3713959A1
(en)
|
2017-11-21 |
2020-09-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
KR102575787B1
(ko)
|
2017-12-21 |
2023-09-08 |
에프. 호프만-라 로슈 아게 |
Hla-a2/wt1에 결합하는 항체
|
|
EP3728321A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Use of pilra binding agents for treatment of a disease
|
|
US11945839B2
(en)
|
2017-12-22 |
2024-04-02 |
Hoffmann-La Roche Inc. |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
US20220135687A1
(en)
|
2017-12-28 |
2022-05-05 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
|
TW201930358A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對ｔｉｇｉｔ之單域抗體及其變異體
|
|
EP3731865A1
(en)
|
2017-12-29 |
2020-11-04 |
F. Hoffmann-La Roche AG |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
|
CN111886246A
(zh)
|
2017-12-29 |
2020-11-03 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
|
EP3735271A4
(en)
|
2018-01-04 |
2022-06-15 |
Iconic Therapeutics, Inc. |
ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
|
|
US11067584B2
(en)
|
2018-01-12 |
2021-07-20 |
Genzyme Corporation |
Methods for the quantitation of polypeptides
|
|
KR20200120641A
(ko)
|
2018-01-15 |
2020-10-21 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
|
CA3088649A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US20210107988A1
(en)
|
2018-01-24 |
2021-04-15 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
|
EP3746480A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
安定化された免疫グロブリンドメイン
|
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
MX2020007527A
(es)
|
2018-02-06 |
2020-09-09 |
Hoffmann La Roche |
Tratamiento de enfermedades oftalmologicas.
|
|
KR20200118065A
(ko)
|
2018-02-08 |
2020-10-14 |
제넨테크, 인크. |
이중특이적 항원-결합 분자 및 이의 사용 방법
|
|
US11884733B2
(en)
|
2018-02-08 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the NKG2D receptor
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
KR20220098056A
(ko)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
JP2021512624A
(ja)
|
2018-02-11 |
2021-05-20 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
|
|
EP3753956A4
(en)
|
2018-02-14 |
2021-12-22 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN BINDING MOLECULE AND COMBINATION
|
|
MX2020009379A
(es)
|
2018-03-12 |
2020-10-14 |
Genmab As |
Anticuerpos.
|
|
CA3092002A1
(en)
|
2018-03-13 |
2019-09-19 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
TWI827585B
(zh)
|
2018-03-15 |
2024-01-01 |
日商中外製藥股份有限公司 |
對茲卡病毒具有交叉反應性的抗登革病毒抗體及其使用方法
|
|
SG11202009542PA
(en)
|
2018-03-29 |
2020-10-29 |
Genentech Inc |
Modulating lactogenic activity in mammalian cells
|
|
TW202003567A
(zh)
|
2018-03-30 |
2020-01-16 |
大陸商南京傳奇生物科技有限公司 |
針對lag-3之單一結構域抗體及其用途
|
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
|
|
CA3096052A1
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
AU2019253462A1
(en)
|
2018-04-09 |
2020-11-26 |
Amgen Inc. |
Growth differentiation factor 15 fusion proteins
|
|
SG11202009804RA
(en)
|
2018-04-11 |
2020-11-27 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
CR20200459A
(es)
|
2018-04-13 |
2020-11-11 |
Hoffmann La Roche |
Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
|
|
CN112437777A
(zh)
|
2018-04-18 |
2021-03-02 |
Xencor股份有限公司 |
包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
|
|
US11524991B2
(en)
|
2018-04-18 |
2022-12-13 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
SG11202010601VA
(en)
|
2018-05-03 |
2020-11-27 |
Genmab Bv |
Antibody variant combinations and uses thereof
|
|
CA3097512A1
(en)
|
2018-05-18 |
2019-11-21 |
F. Hoffmann-La Roche Ag |
Targeted intracellular delivery of large nucleic acids
|
|
US20200109195A1
(en)
|
2018-05-21 |
2020-04-09 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
JP7337099B2
(ja)
|
2018-05-25 |
2023-09-01 |
アレクトル エルエルシー |
抗ｓｉｒｐａ抗体およびその使用法
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
|
AU2019280900A1
(en)
|
2018-06-09 |
2020-11-19 |
Boehringer Ingelheim International Gmbh |
DLL3-CD3 bispecific antibodies
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
SG11202012342WA
(en)
|
2018-06-18 |
2021-01-28 |
Eureka Therapeutics Inc |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
JP7513530B2
(ja)
|
2018-06-22 |
2024-07-09 |
ジェンマブ ホールディング ビー．ブイ． |
抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
|
|
CN112384532A
(zh)
|
2018-06-29 |
2021-02-19 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
|
US11845797B2
(en)
|
2018-07-03 |
2023-12-19 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP3818082A1
(en)
|
2018-07-04 |
2021-05-12 |
F. Hoffmann-La Roche AG |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11396546B2
(en)
|
2018-07-13 |
2022-07-26 |
Alector Llc |
Anti-Sortilin antibodies and methods of use thereof
|
|
JP7534281B2
(ja)
|
2018-07-13 |
2024-08-14 |
ジェンマブ エー／エス |
Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
|
|
PE20211858A1
(es)
|
2018-07-13 |
2021-09-21 |
Genmab As |
Variantes de anticuerpos anti-cd38 y sus usos
|
|
MX2021000745A
(es)
|
2018-07-20 |
2021-03-26 |
Surface Oncology Inc |
Composiciones anti-cd112r y metodos.
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
JP7504027B2
(ja)
|
2018-08-03 |
2024-06-21 |
中外製薬株式会社 |
互いに連結された２つの抗原結合ドメインを含む抗原結合分子
|
|
CA3051549A1
(en)
|
2018-08-09 |
2020-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
|
WO2020032230A1
(ja)
|
2018-08-10 |
2020-02-13 |
中外製薬株式会社 |
抗ｃｄ１３７抗原結合分子およびその使用
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
WO2020045545A1
(ja)
|
2018-08-29 |
2020-03-05 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CA3109067A1
(en)
|
2018-09-10 |
2020-03-19 |
Genentech,Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
US11573226B2
(en)
|
2018-09-10 |
2023-02-07 |
Genentech, Inc. |
Systems and methods for affinity capillary electrophoresis
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
CA3155293A1
(en)
|
2018-09-24 |
2020-04-02 |
The Medical College Of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
|
EP3861025A1
(en)
|
2018-10-01 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules with trivalent binding to cd40
|
|
AU2019355252A1
(en)
|
2018-10-01 |
2021-04-01 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-FAP clone 212
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
AU2019354105A1
(en)
|
2018-10-04 |
2021-04-29 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
|
|
EP3864044A1
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
CN113166263A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
Dll3单域抗体及其治疗性组合物
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
CN113166262A
(zh)
|
2018-10-11 |
2021-07-23 |
英伊布里克斯公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
WO2020077276A2
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
WO2020086758A1
(en)
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
AU2019375014A1
(en)
|
2018-11-06 |
2021-05-27 |
BioNTech SE |
Antibody formulation
|
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
US20230183379A1
(en)
|
2018-11-20 |
2023-06-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
AU2019392711A1
(en)
|
2018-12-05 |
2021-05-20 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック， インコーポレイテッド |
Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
|
EP3897851A2
(en)
|
2018-12-17 |
2021-10-27 |
Revitope Limited |
Twin immune cell engager
|
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
TW202035442A
(zh)
|
2018-12-20 |
2020-10-01 |
美商建南德克公司 |
經修飾之抗體Fc及其使用方法
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
WO2020132646A1
(en)
|
2018-12-20 |
2020-06-25 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
|
JP2022514280A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
Ｍｄｍ２阻害剤のための延長低用量レジメン
|
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
|
TW202039567A
(zh)
|
2018-12-21 |
2020-11-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之促效cd28抗原結合分子
|
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
|
SG11202106100VA
(en)
|
2018-12-21 |
2021-07-29 |
23Andme Inc |
Anti-il-36 antibodies and methods of use thereof
|
|
US11739160B2
(en)
|
2018-12-24 |
2023-08-29 |
Sanofi |
PseudoFab-based multispecific binding proteins
|
|
WO2020136566A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
JP7241888B2
(ja)
|
2018-12-30 |
2023-03-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
ｐＨ勾配ＳＰＲに基づく結合アッセイ
|
|
WO2020142740A1
(en)
|
2019-01-04 |
2020-07-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
|
WO2020146393A1
(en)
*
|
2019-01-07 |
2020-07-16 |
Shattuck Labs. Inc. |
Heterodimeric proteins for modulating gamma delta t cells
|
|
BR112021013507A2
(pt)
|
2019-01-10 |
2021-11-16 |
Janssen Biotech Inc |
Neoantígenos da próstata e seus usos
|
|
CA3127025A1
(en)
|
2019-01-18 |
2020-07-23 |
Janssen Biotech, Inc. |
Gprc5d chimeric antigen receptors and cells expressing the same
|
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
WO2020165834A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054A1
(en)
|
2019-02-15 |
2021-12-22 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
GB2599229B
(en)
|
2019-02-21 |
2024-04-24 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
EP3927745A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
WO2020172596A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and thereof
|
|
WO2020172571A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
|
US20220235144A1
(en)
|
2019-03-04 |
2022-07-28 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
JP7402247B2
(ja)
|
2019-03-08 |
2023-12-20 |
ジェネンテック， インコーポレイテッド |
細胞外小胞の膜結合タンパク質を検出及び定量化するための方法
|
|
AU2020236015A1
(en)
|
2019-03-14 |
2021-09-09 |
Genentech, Inc. |
Treatment of cancer with HER2XCD3 bispecific antibodies in combination with anti-HER2 MAB
|
|
EP3946593A1
(en)
|
2019-03-29 |
2022-02-09 |
Atarga, LLC |
Anti fgf23 antibody
|
|
JP7412440B2
(ja)
|
2019-03-29 |
2024-01-12 |
エフ． ホフマン－ラ ロシュ アーゲー |
アビド結合多重特異性抗体を作製する方法
|
|
EP3948281A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Spr-based binding assay for the functional analysis of multivalent molecules
|
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
|
AU2020258480A1
(en)
|
2019-04-19 |
2021-10-21 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
|
KR20220004062A
(ko)
|
2019-04-25 |
2022-01-11 |
에프. 호프만-라 로슈 아게 |
반감기가 연장된 활성화 가능한 치료용 다중특이적 폴리펩티드
|
|
KR20220005031A
(ko)
|
2019-04-25 |
2022-01-12 |
에프. 호프만-라 로슈 아게 |
폴리펩티드 사슬 교환에 의한 항체-유래된 폴리펩티드의 산출
|
|
TW202106715A
(zh)
|
2019-04-25 |
2021-02-16 |
瑞士商赫孚孟拉羅股份公司 |
藉由多肽鏈交換活化之治療性多特異性多肽
|
|
WO2020225456A1
(en)
|
2019-05-09 |
2020-11-12 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
|
KR20220005568A
(ko)
|
2019-05-09 |
2022-01-13 |
제넨테크, 인크. |
항체의 제조 방법
|
|
CN113811770B
(zh)
|
2019-05-13 |
2024-06-28 |
豪夫迈·罗氏有限公司 |
抑制干扰的药代动力学免疫测定
|
|
MX2021013825A
(es)
|
2019-05-14 |
2022-01-18 |
Genentech Inc |
Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
|
|
UY38701A
(es)
|
2019-05-21 |
2020-12-31 |
Novartis Ag |
Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
|
|
US20220396631A1
(en)
|
2019-05-21 |
2022-12-15 |
Lu HUANG |
Trispecific binding molecules against bcma and uses thereof
|
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
|
CR20220008A
(es)
|
2019-06-10 |
2022-02-11 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de citocinas
|
|
JP7512310B2
(ja)
|
2019-06-11 |
2024-07-08 |
アレクトル エルエルシー |
治療に使用するための抗ソルチリン抗体
|
|
BR112021025436A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Métodos para produzir um anticorpo biespecífico trivalente, biespecífico bivalente, biespecífico multivalente, para produzir uma célula de mamífero recombinante e para produzir um anticorpo trivalente, ácidos desoxirribonucleicos, usos de um ácido desoxirribonucleico, células de mamífero recombinante, composições e uso de mrna de recombinase cre
|
|
EP3986927A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
MX2021015538A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
|
|
AU2020296247A1
(en)
|
2019-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
JP7410983B2
(ja)
|
2019-06-19 |
2024-01-10 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｃｒｅ ｍＲＮＡを使用した標的指向性組込みによるタンパク質発現細胞の作製のための方法
|
|
JP7450647B2
(ja)
|
2019-06-26 |
2024-03-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｓｉｒｔ－１遺伝子ノックアウトを有する哺乳類細胞株
|
|
BR112021026293A2
(pt)
|
2019-06-26 |
2022-03-03 |
Hoffmann La Roche |
Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
|
|
CN114531878A
(zh)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
|
|
MX2021015791A
(es)
|
2019-06-28 |
2022-04-01 |
Amgen Inc |
Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
KR20220034857A
(ko)
|
2019-07-16 |
2022-03-18 |
사노피 |
알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
KR20220028035A
(ko)
|
2019-07-31 |
2022-03-08 |
에프. 호프만-라 로슈 아게 |
Gprc5d에 결합하는 항체
|
|
CN114341181A
(zh)
|
2019-07-31 |
2022-04-12 |
艾莱克特有限责任公司 |
抗ms4a4a抗体及其使用方法
|
|
JP7181438B2
(ja)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
病理学的タウ種に結合する抗体及びその使用
|
|
MX2022001682A
(es)
|
2019-08-08 |
2022-05-13 |
Regeneron Pharma |
Nuevos formatos de moleculas de union a antigenos.
|
|
CR20220111A
(es)
|
2019-08-13 |
2022-05-04 |
Amgen Inc |
Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
|
|
MX2022002612A
(es)
|
2019-09-03 |
2022-05-06 |
Amgen Inc |
Composiciones de il-22 orales, intrarrectales u otras relacionadas con el intestino y metodos de uso de las mismas.
|
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
|
CA3150999A1
(en)
|
2019-09-18 |
2021-03-25 |
James Thomas Koerber |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
CN114423454A
(zh)
|
2019-09-20 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体的给药
|
|
US20220281997A1
(en)
|
2019-09-27 |
2022-09-08 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-VHH Domain Antibodies and Use Thereof
|
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
|
US20240301053A1
(en)
|
2019-10-21 |
2024-09-12 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
|
CN114786730A
(zh)
|
2019-11-05 |
2022-07-22 |
再生元制药公司 |
N-端scFv多特异性结合分子
|
|
EP4055046A1
(en)
|
2019-11-06 |
2022-09-14 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
|
US20220389119A1
(en)
|
2019-11-08 |
2022-12-08 |
Amgen Inc. |
ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
|
|
BR112022008172A2
(pt)
|
2019-11-15 |
2022-07-12 |
Hoffmann La Roche |
Composição aquosa estável, método para obter uma composição e forma de dosagem farmacêutica
|
|
JP2023502652A
(ja)
|
2019-11-18 |
2023-01-25 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ７９キメラ抗原受容体、ｃａｒ－ｔ細胞、及びそれらの使用
|
|
JP2023501717A
(ja)
|
2019-11-19 |
2023-01-18 |
アムジエン・インコーポレーテツド |
新規の多重特異性抗体フォーマット
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
CN113135996A
(zh)
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
|
BR112022011949A2
(pt)
|
2019-12-17 |
2022-11-22 |
Amgen Inc |
Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
|
|
CN115397853A
(zh)
|
2019-12-17 |
2022-11-25 |
辉瑞大药厂 |
对cd47、pd-l1具特异性的抗体及其用途
|
|
CR20220277A
(es)
|
2019-12-18 |
2022-08-31 |
Hoffmann La Roche |
Anticuerpos anti-ccl2 biespecifico
|
|
WO2021122875A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/mage-a4
|
|
TW202136316A
(zh)
|
2019-12-20 |
2021-10-01 |
美商再生元醫藥公司 |
新穎之il2促效劑及其使用方法(一)
|
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
|
EP4077363A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Il-37 fusion proteins and uses thereof
|
|
BR112022012439A2
(pt)
|
2019-12-23 |
2022-09-06 |
Genentech Inc |
Anticorpos isolados, ácido nucleico isolado, vetor isolado, célula hospedeira isolada e métodos para produzir um anticorpo que se liga à apol1, para detectar apolipoproteína l1 em uma amostra, para distinguir apolipoproteína l1 endógena, para distinguir as formas g0 e g1 de apolipoproteína l1 da forma apol1 g2 e para detectar especificamente células de podócitos
|
|
KR102645629B1
(ko)
|
2019-12-27 |
2024-03-07 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체 및 그의 사용
|
|
CN114930170A
(zh)
|
2020-01-02 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
用于测定脑中的治疗性抗体量的方法
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
IL292780A
(en)
|
2020-01-09 |
2022-07-01 |
Hoffmann La Roche |
A new 4-1bbl trimer containing antigen-binding molecules
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
CN114981284A
(zh)
|
2020-01-15 |
2022-08-30 |
豪夫迈·罗氏有限公司 |
减少来自重组蛋白生产过程中的杂质的方法
|
|
JP2023510397A
(ja)
|
2020-01-16 |
2023-03-13 |
ジェンマブ エー／エス |
Ｃｄ３８抗体の製剤およびその使用
|
|
EP4090762A1
(en)
|
2020-01-17 |
2022-11-23 |
Becton, Dickinson and Company |
Methods and compositions for single cell secretomics
|
|
CN114980902A
(zh)
|
2020-01-17 |
2022-08-30 |
诺华股份有限公司 |
用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合
|
|
BR112022014667A2
(pt)
|
2020-01-29 |
2022-09-20 |
Inhibrx Inc |
Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
EP4105237A4
(en)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co., Ltd. |
ANTI-CLDN18.2 ANTIBODIES AND ITS USE
|
|
KR20220140786A
(ko)
|
2020-02-10 |
2022-10-18 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
클라우딘18.2 항체 및 그것의 사용
|
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
CA3173257A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
|
US20230174933A1
(en)
|
2020-02-27 |
2023-06-08 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
|
BR112022015572A2
(pt)
|
2020-03-18 |
2022-09-27 |
Genmab As |
Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes
|
|
EP4121163A1
(en)
|
2020-03-19 |
2023-01-25 |
Genentech, Inc. |
Isoform-selective anti-tgf-beta antibodies and methods of use
|
|
WO2021194913A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
KR20220156912A
(ko)
|
2020-03-25 |
2022-11-28 |
일라이 릴리 앤드 캄파니 |
다중특이적 결합 단백질 및 그의 개발 방법
|
|
KR20220159426A
(ko)
|
2020-03-26 |
2022-12-02 |
제넨테크, 인크. |
감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
|
|
JP2023520773A
(ja)
|
2020-03-27 |
2023-05-19 |
ノバルティス アーゲー |
増殖性疾患及び自己免疫疾患を治療するための二重特異性組合せ治療
|
|
TW202204407A
(zh)
|
2020-03-30 |
2022-02-01 |
國立大學法人三重大學 |
雙特異性抗體
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
US20240183826A9
(en)
|
2020-04-02 |
2024-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
BR112022020629A2
(pt)
|
2020-04-15 |
2022-11-29 |
Hoffmann La Roche |
Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
|
|
CN116249712A
(zh)
|
2020-04-15 |
2023-06-09 |
沃雅戈治疗公司 |
Tau结合化合物
|
|
CA3180321A1
(en)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
US20230265204A1
(en)
|
2020-04-24 |
2023-08-24 |
Hoffmann-La Roche Inc. |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
|
WO2021217051A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
AU2021263408A1
(en)
|
2020-04-30 |
2022-10-27 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁（苏州）生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
|
AU2021267402A1
(en)
|
2020-05-08 |
2022-11-24 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
|
CR20220576A
(es)
|
2020-05-11 |
2022-12-07 |
Hoffmann La Roche |
Tratamiento conjunto con pbmc modificadas y un inmunoconjugado
|
|
KR20230009430A
(ko)
|
2020-05-12 |
2023-01-17 |
리제너론 파아마슈티컬스, 인크. |
신규 il10 효능제 및 그의 사용 방법
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
EP4149421A1
(en)
|
2020-05-15 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Prevention of visible particle formation in parenteral protein solutions
|
|
JP7547507B2
(ja)
|
2020-05-18 |
2024-09-09 |
山▲東▼先声生物制▲薬▼有限公司 |
ヒトｉｌ－１５変異体およびその使用
|
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
|
JP2023504675A
(ja)
|
2020-05-19 |
2023-02-06 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ガンの処置のための結合分子
|
|
BR112022024339A2
(pt)
|
2020-05-29 |
2022-12-27 |
23Andme Inc |
Anticorpos anti cd200r1 e métodos de uso dos mesmos
|
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック， インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
|
EP4168447A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and cd19
|
|
TW202214286A
(zh)
|
2020-06-19 |
2022-04-16 |
日商中外製藥股份有限公司 |
用於與血管新生抑制劑組合使用之抗t細胞抗原結合分子
|
|
CR20220639A
(es)
|
2020-06-19 |
2023-02-17 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1
|
|
CA3176552A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Immune activating fc domain binding molecules
|
|
WO2021255142A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
AU2021291002A1
(en)
|
2020-06-19 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Protease-activated T cell bispecific antibodies
|
|
WO2021259880A1
(en)
|
2020-06-22 |
2021-12-30 |
Almirall, S.A. |
Anti-il-36 antibodies and methods of use thereof
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
JP2023530760A
(ja)
|
2020-06-23 |
2023-07-19 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２を標的とするアゴニストＣＤ２８抗原結合分子
|
|
KR20230026491A
(ko)
|
2020-06-24 |
2023-02-24 |
제넨테크, 인크. |
아폽토시스 내성 세포주
|
|
EP4172203A1
(en)
|
2020-06-25 |
2023-05-03 |
F. Hoffmann-La Roche AG |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
EP4178529A1
(en)
|
2020-07-07 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
EP4178985A1
(en)
|
2020-07-10 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
|
JP2023534214A
(ja)
|
2020-07-16 |
2023-08-08 |
ノバルティス アーゲー |
抗ベータセルリン抗体、その断片、及び多重特異性結合分子
|
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
|
WO2022016119A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
AR123019A1
(es)
|
2020-07-21 |
2022-10-26 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos
|
|
JP2023534726A
(ja)
|
2020-07-23 |
2023-08-10 |
ジェンマブ ビー．ブイ． |
多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
MX2023001120A
(es)
|
2020-07-31 |
2023-02-22 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica que comprende una celula que expresa un receptor quimerico.
|
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CN116194477A
(zh)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
冠状病毒s蛋白的结合剂
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
KR20230074144A
(ko)
|
2020-08-26 |
2023-05-26 |
마렝고 테라퓨틱스, 인크. |
NKp30에 결합하는 항체 분자 및 이의 용도
|
|
EP4204458A1
(en)
|
2020-08-26 |
2023-07-05 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
CN116249718A
(zh)
|
2020-08-26 |
2023-06-09 |
马伦戈治疗公司 |
结合至钙网蛋白的多功能性分子及其用途
|
|
WO2022044248A1
(ja)
|
2020-08-28 |
2022-03-03 |
中外製薬株式会社 |
ヘテロ二量体Ｆｃポリペプチド
|
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
BR112023003868A2
(pt)
|
2020-09-02 |
2023-04-04 |
Genmab As |
Método para prevenir ou reduzir o crescimento de um tumor, agente de ligação para uso em prevenir ou reduzir o crescimento de tumor, composição imunogênica compreendendo pelo menos um antígeno de vacina para uso, usos de um agente de ligação e de uma composição imunogênica, e, kit de partes compreendendo um agente de ligação
|
|
WO2022053658A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
AU2021340232A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against CD3 and CD20 in combination therapy for treating diffuse large B-cell lymphoma
|
|
US20230312758A1
(en)
|
2020-09-10 |
2023-10-05 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
MX2023002542A
(es)
|
2020-09-10 |
2023-03-15 |
Genmab As |
Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
|
|
AU2021341509A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
|
|
BR112023004327A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar leucemia linfocítica crônica em um sujeito humano
|
|
WO2022053715A1
(en)
|
2020-09-14 |
2022-03-17 |
Ichnos Sciences SA |
Antibodies that bind to il1rap and uses thereof
|
|
EP4214244A1
(en)
|
2020-09-21 |
2023-07-26 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
MX2023003328A
(es)
|
2020-09-24 |
2023-03-27 |
Hoffmann La Roche |
Lineas de celulas de mamifero con desactivacion genica.
|
|
MX2023003749A
(es)
|
2020-10-02 |
2023-04-24 |
Genmab As |
Anticuerpos capaces de unirse al receptor huerfano 2 similar a tirosina-cinasa receptora (ror2) y anticuerpos biespecificos que se unen a ror2 y al cumulo de diferenciacion 3 (cd3).
|
|
KR20230082632A
(ko)
|
2020-10-05 |
2023-06-08 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체를 사용한 치료를 위한 투약
|
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022084355A2
(en)
|
2020-10-21 |
2022-04-28 |
Boehringer Ingelheim International Gmbh |
Agonistic trkb binding molecules for the treatment of eye diseases
|
|
EP4237003A1
(en)
|
2020-10-28 |
2023-09-06 |
Janssen Biotech, Inc. |
Compositions and methods for modulating delta gamma chain mediated immunity
|
|
EP4237451A1
(en)
|
2020-11-02 |
2023-09-06 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
CN117120477A
(zh)
|
2020-11-10 |
2023-11-24 |
上海齐鲁制药研究中心有限公司 |
针对密蛋白18a2和cd3的双特异性抗体及其应用
|
|
JP2023549504A
(ja)
|
2020-11-13 |
2023-11-27 |
ノバルティス アーゲー |
キメラ抗原受容体（ｃａｒ）発現細胞との組合せ療法
|
|
CR20230253A
(es)
|
2020-11-16 |
2023-07-26 |
Hoffmann La Roche |
Glucoformas de fab ricas en manosa
|
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
|
CA3202986A1
(en)
|
2020-12-02 |
2022-06-09 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
|
MX2023006480A
(es)
|
2020-12-04 |
2023-06-19 |
Hoffmann La Roche |
Polipeptidos de interleucina-2 mutante dependientes del ph.
|
|
AU2021395729A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
WO2022122652A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
KR20230120665A
(ko)
|
2020-12-17 |
2023-08-17 |
에프. 호프만-라 로슈 아게 |
항-hla-g 항체 및 이의 용도
|
|
CN116601175A
(zh)
|
2020-12-18 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
用于靶向疗法的前体蛋白和试剂盒
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
CA3207090A1
(en)
|
2021-01-06 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
AU2022207615A1
(en)
|
2021-01-12 |
2023-07-13 |
F. Hoffmann-La Roche Ag |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
JP2024503654A
(ja)
|
2021-01-13 |
2024-01-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
併用療法
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2022162569A1
(en)
|
2021-01-29 |
2022-08-04 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
WO2022169872A1
(en)
|
2021-02-03 |
2022-08-11 |
Genentech, Inc. |
Multispecific binding protein degrader platform and methods of use
|
|
CN117794566A
(zh)
|
2021-02-05 |
2024-03-29 |
Vib研究所 |
沙贝病毒结合剂
|
|
JP2024506694A
(ja)
|
2021-02-16 |
2024-02-14 |
ヤンセン バイオテツク，インコーポレーテツド |
増強されたリンカー標的化のための材料及び方法
|
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
|
CN116964095A
(zh)
|
2021-02-19 |
2023-10-27 |
沙裴隆有限公司 |
针对cd47的单域抗体及其用途
|
|
WO2022177393A1
(ko)
|
2021-02-19 |
2022-08-25 |
(주)샤페론 |
Pd-l1에 대한 단일 도메인 항체 및 이의 용도
|
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート
|
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
|
WO2022189380A1
(en)
|
2021-03-09 |
2022-09-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック， インコーポレイテッド |
抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
|
|
EP4305056A1
(en)
|
2021-03-12 |
2024-01-17 |
Genmab A/S |
Non-activating antibody variants
|
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
|
WO2022197947A1
(en)
|
2021-03-18 |
2022-09-22 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
EP4314063A1
(en)
|
2021-03-23 |
2024-02-07 |
Alector LLC |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
MX2023011340A
(es)
|
2021-03-26 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
|
|
KR20230162013A
(ko)
|
2021-03-26 |
2023-11-28 |
이나뜨 파르마 에스.에이. |
Nk 세포 관여를 위해 사이토카인에 융합된 nkp46-결합 부위, 암 항원 결합 부위를 포함하는 다중특이적 단백질
|
|
WO2022210485A1
(ja)
|
2021-03-29 |
2022-10-06 |
第一三共株式会社 |
安定な多重特異性分子及びその利用
|
|
CA3237992A1
(en)
|
2021-03-31 |
2022-10-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Truncated taci polypeptide and fusion protein and use thereof
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
|
JP2024513474A
(ja)
|
2021-04-09 |
2024-03-25 |
エフ． ホフマン－ラ ロシュ アーゲー |
異種ポリペプチドを発現する細胞クローンを選択するための方法
|
|
TW202304524A
(zh)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1結合劑、其結合物及使用方法
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
KR20230173164A
(ko)
|
2021-04-19 |
2023-12-26 |
제넨테크, 인크. |
변형된 포유류 세포
|
|
TW202308699A
(zh)
|
2021-04-23 |
2023-03-01 |
美商普方生物製藥美國公司 |
Ｃｄ７０結合劑、其結合物及其使用方法
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
|
BR112023022844A2
(pt)
|
2021-05-03 |
2024-01-23 |
UCB Biopharma SRL |
Anticorpos
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
BR112023022878A2
(pt)
|
2021-05-04 |
2024-01-23 |
Regeneron Pharma |
Agonistas do receptor fgf21 multiespecíficos e seus usos
|
|
WO2022234146A1
(en)
|
2021-05-07 |
2022-11-10 |
Genmab A/S |
PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
|
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
|
MX2023013264A
(es)
|
2021-05-12 |
2023-11-30 |
Genentech Inc |
Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
|
|
US20240254245A1
(en)
|
2021-05-12 |
2024-08-01 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof
|
|
CA3219388A1
(en)
|
2021-05-14 |
2022-11-17 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule
|
|
CN117396510A
(zh)
|
2021-05-14 |
2024-01-12 |
基因泰克公司 |
Trem2的激动剂
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
JP2024521107A
(ja)
|
2021-05-21 |
2024-05-28 |
ジェネンテック， インコーポレイテッド |
目的の組換え産物を産生するための修飾細胞
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
TW202306994A
(zh)
|
2021-06-04 |
2023-02-16 |
日商中外製藥股份有限公司 |
抗ddr2抗體及其用途
|
|
EP4352098A1
(en)
|
2021-06-09 |
2024-04-17 |
Innate Pharma |
Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
|
|
AU2022289684A1
(en)
|
2021-06-09 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
WO2022258673A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
CN117957256A
(zh)
|
2021-06-17 |
2024-04-30 |
勃林格殷格翰国际有限公司 |
新颖三特异性结合分子
|
|
KR20240021859A
(ko)
|
2021-06-18 |
2024-02-19 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
|
US20240262924A1
(en)
|
2021-06-21 |
2024-08-08 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
|
JP2023535884A
(ja)
|
2021-06-22 |
2023-08-22 |
ノバルティス アーゲー |
化膿性汗腺炎の処置における使用のための二特異性抗体
|
|
EP4359083A1
(en)
|
2021-06-24 |
2024-05-01 |
Erasca, Inc. |
Antibodies against egfr and their uses
|
|
CN117616123A
(zh)
|
2021-06-25 |
2024-02-27 |
中外制药株式会社 |
抗ctla-4抗体
|
|
BR112023023480A2
(pt)
|
2021-06-25 |
2024-01-30 |
Chugai Pharmaceutical Co Ltd |
Uso de anticorpo anti-ctla-4
|
|
CN117580865A
(zh)
|
2021-06-29 |
2024-02-20 |
山东先声生物制药有限公司 |
Cd16抗体及其应用
|
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
IL309559A
(en)
|
2021-07-09 |
2024-02-01 |
Luxembourg Inst Of Health Lih |
Dimeric protein complexes and their uses
|
|
EP4371125A1
(en)
|
2021-07-13 |
2024-05-22 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
|
WO2023284829A1
(zh)
|
2021-07-14 |
2023-01-19 |
江苏恒瑞医药股份有限公司 |
特异性结合hgfr和egfr的抗原结合分子及其医药用途
|
|
EP4370553A1
(en)
|
2021-07-14 |
2024-05-22 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
JP2024528665A
(ja)
|
2021-07-19 |
2024-07-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ１２受容体アゴニスト及びその使用方法
|
|
EP4373576A1
(en)
|
2021-07-22 |
2024-05-29 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
CN117715939A
(zh)
|
2021-07-27 |
2024-03-15 |
莫佛塞斯公司 |
抗原结合分子的组合
|
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
|
EP4377351A1
(en)
|
2021-07-28 |
2024-06-05 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer
|
|
EP4380980A1
(en)
|
2021-08-03 |
2024-06-12 |
F. Hoffmann-La Roche AG |
Bispecific antibodies and methods of use
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
KR20240046251A
(ko)
|
2021-08-16 |
2024-04-08 |
리제너론 파아마슈티컬스, 인크. |
신규 il27 수용체 효능제 및 그의 사용 방법
|
|
CN118284623A
(zh)
|
2021-08-23 |
2024-07-02 |
伊莫尼塔斯治疗公司 |
抗cd161抗体及其用途
|
|
KR20240049296A
(ko)
|
2021-08-27 |
2024-04-16 |
제넨테크, 인크. |
타우 병증을 치료하는 방법
|
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
IL311141A
(en)
|
2021-09-06 |
2024-04-01 |
Genmab As |
Antibodies capable of binding to CD27, their variants and uses thereof
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4406968A1
(en)
|
2021-09-23 |
2024-07-31 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-klb antibodies and uses
|
|
EP4410841A1
(en)
|
2021-09-30 |
2024-08-07 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-il23 antibody fusion protein and uses thereof
|
|
CN118562018A
(zh)
*
|
2021-09-30 |
2024-08-30 |
宁波三生生物科技股份有限公司 |
重组促卵泡激素融合蛋白
|
|
CN118414353A
(zh)
|
2021-10-08 |
2024-07-30 |
根马布股份公司 |
与cd30和cd3结合的抗体
|
|
WO2023058705A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
抗ｈｌａ－ｄｑ２．５抗体の製剤
|
|
CA3234966A1
(en)
|
2021-10-14 |
2023-04-20 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
CA3234731A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
|
EP4415822A1
(en)
|
2021-10-15 |
2024-08-21 |
RegenxBio Inc. |
Antibodies and methods of using thereof
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
CN118119642A
(zh)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
工程化Fc变体
|
|
EP4430072A1
(en)
|
2021-11-10 |
2024-09-18 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
US20230279153A1
(en)
|
2021-11-11 |
2023-09-07 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Antibodies masked in protease-wells
|
|
CA3239389A1
(en)
|
2021-12-01 |
2023-06-08 |
Kohei SOEDA |
Method for preparing antibody-containing formulation
|
|
EP4428156A1
(en)
|
2021-12-03 |
2024-09-11 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Anti-bcma nanobody and use thereof
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
CN118574849A
(zh)
|
2021-12-17 |
2024-08-30 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体和使用方法
|
|
AU2022423749A1
(en)
|
2021-12-20 |
2024-06-13 |
F. Hoffmann-La Roche Ag |
Agonistic ltbr antibodies and bispecific antibodies comprising them
|
|
CN118401674A
(zh)
|
2021-12-21 |
2024-07-26 |
豪夫迈·罗氏有限公司 |
用于确定水解活性的方法
|
|
WO2023116861A1
(zh)
|
2021-12-23 |
2023-06-29 |
江苏恒瑞医药股份有限公司 |
抗dll3抗体、其抗体-药物偶联物及其医药用途
|
|
WO2023125888A1
(zh)
|
2021-12-31 |
2023-07-06 |
山东先声生物制药有限公司 |
一种gprc5d抗体及其应用
|
|
WO2023135198A1
(en)
|
2022-01-12 |
2023-07-20 |
Vib Vzw |
Human ntcp binders for therapeutic use and liver-specific targeted delivery
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
IL314344A
(en)
|
2022-01-28 |
2024-09-01 |
Genmab As |
Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
|
WO2023144306A1
(en)
|
2022-01-28 |
2023-08-03 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
CN118574855A
(zh)
|
2022-02-07 |
2024-08-30 |
江苏恒瑞医药股份有限公司 |
特异性结合psma和cd3的抗原结合分子及其医药用途
|
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
WO2023166420A1
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
TW202400636A
(zh)
|
2022-03-11 |
2024-01-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(一)
|
|
WO2023170295A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
|
TW202346365A
(zh)
|
2022-03-23 |
2023-12-01 |
瑞士商赫孚孟拉羅股份公司 |
抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
|
|
WO2023179740A1
(en)
|
2022-03-25 |
2023-09-28 |
Shanghai Henlius Biotech , Inc. |
Anti-msln antibodies and methods of use
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20230406930A1
(en)
|
2022-04-13 |
2023-12-21 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
|
TW202404637A
(zh)
|
2022-04-13 |
2024-02-01 |
瑞士商赫孚孟拉羅股份公司 |
抗ｃｄ２０／抗ｃｄ３雙特異性抗體之醫藥組成物及使用方法
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
WO2023218046A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
US20240228664A9
(en)
|
2022-07-22 |
2024-07-11 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
|
TW202417504A
(zh)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
抗ｓｔｅａｐ１抗原結合分子及其用途
|
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
US20240052047A1
(en)
|
2022-08-03 |
2024-02-15 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
TW202421664A
(zh)
|
2022-10-07 |
2024-06-01 |
美商建南德克公司 |
用抗ｃ—ｃ模體趨化因子受體８（ｃｃｒ８）抗體治療癌症之方法
|
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024094660A1
(en)
|
2022-10-31 |
2024-05-10 |
Genmab A/S |
Cd38 antibodies and uses thereof
|
|
WO2024094822A1
(en)
|
2022-11-02 |
2024-05-10 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
|
WO2024104988A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with activatable effector domain
|
|
US20240226313A1
(en)
|
2022-11-17 |
2024-07-11 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
|
EP4385999A1
(en)
|
2022-12-14 |
2024-06-19 |
ModiQuest B.V. |
Antibodies
|
|
WO2024126660A1
(en)
|
2022-12-15 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Combination therapy for cancer treatment
|
|
WO2024130175A2
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
WO2024152014A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
US20240270836A1
(en)
|
2023-01-13 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
WO2024155807A1
(en)
|
2023-01-18 |
2024-07-25 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
|
WO2024153722A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
WO2024156759A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Payload-bearing multispecific antibodies
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
WO2024165454A1
(en)
|
2023-02-06 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Combination therapy and uses thereof
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024178056A1
(en)
|
2023-02-21 |
2024-08-29 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
|
US20240309072A1
(en)
|
2023-02-28 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Multivalent anti-spike protein binding molecules and uses thereof
|
|
US20240287186A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|